A Single Peptide That Activates Both GLP-1 and CCK Receptors Improved Diabetes and Weight in Mice

The study first established the individual and combined effects of GLP-1 and CCK1 receptor activation on pancreatic beta cells in vitro. Researchers then characterized the bioactivity of an acylated (lipid-modified for longer action) dual-acting GLP-1/CCK hybrid peptide called [Lys12Pal]Ex-4/CCK. For the in vivo study, male C57BL mice were placed on a high-fat diet and given streptozotocin (STZ) to damage their beta cells, creating a model of obesity-related type 2 diabetes. Mice were treated with the hybrid peptide for 28 days, with measurements of blood glucose, body weight, insulin secretion, and beta-cell function markers.

Current GLP-1 drugs are already revolutionary for diabetes and obesity treatment, but they only target one pathway. CCK is another powerful satiety hormone that works through different mechanisms. Combining both signals in a single molecule could provide stronger appetite suppression, better blood sugar control, and more robust beta-cell protection than GLP-1 alone — potentially representing the next evolution beyond today's single- and dual-agonist drugs.

The trend in metabolic drug development is moving from single targets (GLP-1 alone, like semaglutide) to dual agonists (GLP-1/GIP, like tirzepatide) to triple agonists (GLP-1/GIP/glucagon, like retatrutide). This study explores yet another combination — GLP-1 with CCK — expanding the repertoire of multi-receptor approaches. As researchers discover that different gut hormones provide complementary metabolic benefits, the number of possible combinations continues to grow, each potentially offering unique advantages for different patient populations.

This was an animal study in mice with chemically induced diabetes, which doesn't perfectly replicate human type 2 diabetes. The abstract contains formatting artifacts that obscure some specific statistical values. The hybrid peptide has not been tested in humans. The 28-day treatment period is relatively short for assessing long-term efficacy and safety. High-fat-diet/STZ mouse models, while useful, may overestimate treatment effects compared to the slower progression of human disease.